Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 7/20 | 0.57 |
| ▸ | CDK4 | P11802 | 5/20 | 0.57 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.57 |
| ▸ | PLK1 | P53350 | 1/20 | 0.57 |
| ▸ | PIK3CG | P48736 | 7/20 | 0.54 |
| ▸ | CDK9 | P50750 | 5/20 | 0.54 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.54 |
| ▸ | AURKA | O14965 | 3/20 | 0.53 |
| ▸ | CDK1 | P06493 | 3/20 | 0.53 |
| ▸ | CDK7 | P50613 | 3/20 | 0.53 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.53 |
| ▸ | WEE1 | P30291 | 1/20 | 0.53 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.53 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.52 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.52 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1890923 | 0.92 | PIK3CG (0.60) | CDK2CDK4CCNA2PLK1PIK3CG | |
| SCHEMBL30199424 | 0.89 | CDK2 (0.56) | CDK2CDK4CCNA2PLK1PIK3CG | |
| SCHEMBL1889193 | 0.85 | PIK3CG (0.58) | PIK3CGPIK3CDPIK3CAPIK3CBMEN1 | |
| SCHEMBL2285606 | 0.84 | CDK2 (0.67) | CDK2CDK4CCNA2PLK1PIK3CG | |
| SCHEMBL23068648 | 0.83 | CDK2 (0.55) | CDK2CDK4CCNA2PLK1CDK9 | |
| SCHEMBL6363136 | 0.83 | CDK2 (0.76) | CDK2CDK4CCNA2PLK1CDK9 | |
| SCHEMBL22684851 | 0.83 | CDK2 (0.56) | CDK2CDK4CCNA2PLK1CDK9 | |
| SCHEMBL1887212 | 0.82 | PIK3CG (0.55) | PIK3CGPIK3CDPIK3CAPIK3CBMEN1 | |
| SCHEMBL23068667 | 0.82 | CDK2 (0.55) | CDK2CDK4CCNA2PLK1CDK9 | |
| SCHEMBL23068687 | 0.82 | SMN1; SMN2 (0.59) | CDK2CDK4CCNA2PLK1CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2157091-B1 | Inhibitors of phosphatidylinositol 3-kinase | NOVARTIS AG (CH) | 2015-06-10 | — | — | EP | disclosed |
| US-20130172349-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | NOVARTIS AG (CH) | 2013-07-04 | — | — | US | disclosed |
| US-8404684-B2 | Inhibitors of phosphatidylinositol 3-kinase | NOVARTIS AG (CH) | 2013-03-26 | — | — | US | disclosed |
| US-20110105535-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | NOVARTIS AG | 2011-05-05 | — | — | US | disclosed |
| CN-1816549-B | Phosphatidylinositol 3-kinase inhibitors | NOVARTIS AG | 2010-09-29 | — | — | CN | disclosed |
| EP-2157091-A1 | Inhibitors of phosphatidylinositol 3-kinase | Novartis AG (CH) | 2010-02-24 | — | — | EP | disclosed |
| CN-101648949-A | inhibitors of phosphatidylinositol 3-kinase | NOVARTIS AG CH | 2010-02-17 | — | — | CN | disclosed |
| EP-1622897-B1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | NOVARTIS AG (CH) | 2009-10-14 | — | — | EP | disclosed |
| US-20070032487-A1 | Inhibitors of phosphatidylinositol 3-kinase | NOVARTIS AG (CH) | 2007-02-08 | — | — | US | disclosed |
| CN-1816549-A | Phosphatidylinositol 3-kinase inhibitors | NOVARTIS AG (CH) | 2006-08-09 | — | — | CN | disclosed |
| EP-1622897-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | Novartis AG (CH) | 2006-02-08 | — | — | EP | disclosed |
| WO-2004096797-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | NOVARTIS AG (CH) | 2004-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032487-A1 | Inhibitors of phosphatidylinositol 3-kinase | PIK3CA, PIP4K2C, PIP4K2B | CDK2 131/4885CDK4 454/4885CCNA2 891/4885 |
| US-20110105535-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | PIK3CA, PIK3CD, PIP4K2C | CDK2 133/4885CDK4 443/4885CCNA2 886/4885 |
| US-20130172349-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | PIK3CA, PIK3CD, PIP4K2C | CDK2 133/4885CDK4 443/4885CCNA2 886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.